Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood glucose control in adults with type 2 diabetes mellitus and, in specific formulations and eligible patients, for chronic weight management. It works by enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and increasing satiety, thereby helping reduce blood glucose levels and food intake. It is commonly available as a subcutaneous injection in prefilled pens, administered once daily with gradual dose escalation according to the prescribed indication. Common side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during treatment initiation or dose increases. Important precautions include the risk of pancreatitis, gallbladder disorders, dehydration-related kidney problems, and hypoglycaemia when used with insulin or sulfonylureas; it is generally not recommended in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Liraglutide should be used under medical supervision, alongside appropriate dietary and lifestyle measures.
Liraglutide was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Liraglutide, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Liraglutide from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Liraglutide, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
